## RSC Chemical Biology



## CORRECTION



**Cite this:** *RSC Chem. Biol.*, 2021, **2**, 670

## Correction: Fragment-based covalent ligand discovery

Wenchao Lu,<sup>ab</sup> Milka Kostic,<sup>a</sup> Tinghu Zhang,<sup>ab</sup> Jianwei Che,<sup>abc</sup> Matthew P. Patricelli,<sup>d</sup> Lyn H. Jones,<sup>c</sup> Edward T. Chouchani<sup>ae</sup> and Nathanael S. Gray\*<sup>ab</sup>

DOI: 10.1039/d1cb90008k

rsc.li/rsc-chembio

Correction for 'Fragment-based covalent ligand discovery' by Wenchao Lu *et al., RSC Chem. Biol.,* 2021, DOI: 10.1039/d0cb00222d.

The authors regret that an incorrect version of Fig. 2 was included in the original article, where the structure of Sulfopin in Fig. 2D was incorrectly shown. The correct version of Fig. 2 is presented below.


<sup>a</sup> Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. E-mail: nathanael\_gray@dfci.harvard.edu

<sup>b</sup> Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02215, USA

<sup>c</sup> Center for Protein Degradation, Dana-Farber Cancer Institute, Boston, MA 02215, USA

<sup>e</sup> Department of Cell Biology, Harvard Medical School, Boston, MA 02215, USA

<sup>&</sup>lt;sup>d</sup> Vividion Therapeutics, La Jolla, CA 92121, USA



(Douangamath et al. 2020)

**Fig. 2** The structures of representative well-characterized electrophilic fragments identified from target-based screening strategies in recent years. (A) KRAS-G12C allele-specific covalent fragment (6H05) identified from tethering screen, which was further elaborated to compound 12.<sup>31</sup> This inspired numerous groups to develop further optimized inhibitors, within which AMG510<sup>33</sup> and MRTX849<sup>36</sup> successfully entered clinical trials. (B) Compound 5 targets the active cysteine (C885) of HOIP.<sup>37</sup> (C) OTUB2-COV-1 targets the active cysteine (C51) of OTUB2 and NUDT7-COV-1 target C73 of NUDT7.<sup>38</sup> (D) Sulfopin targets the active cysteine of Pin1 (C113).<sup>39</sup> (E) Representative covalent fragment scaffolds target the active cysteine (C145) of SARS-COV-2 main protease (Mpro).<sup>40</sup>

The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.